文献速递免疫规划传染病防控与疫情报告

年轻成人接种第三剂麻腮风疫苗后的风疹病毒中和抗体应答

Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.
PubMed 文献 · Vaccine · 2018-08-11

研究纳入679名已接种两剂麻腮风疫苗的18-31岁年轻成人,在2009年7月至2010年10月间接种第三剂,评估风疹中和抗体。接种前1.8%抗体滴度低于10 U/ml;接种后1个月平均滴度升高4.5倍,超过50%参与者获4倍提升;1年后平均滴度下降但仍显著高于接种前。结论为第三剂可稳健增强风疹中和抗体应答并维持1年。

要点

  • 接种前约15年(距第二剂),1.8%的679名参与者风疹抗体滴度低于10 U/ml。
  • 第三剂后1个月平均滴度升高4.5倍,超过50%参与者获4倍提升。
  • 接种前滴度低于10 U/ml者应答最高,几何平均滴度比为18.8,92%血清阳转。

核心结论

  • 接种第三剂麻腮风疫苗可稳健增强风疹中和抗体应答,且1年后仍高于接种前水平。
  • 风疹抗体滴度低的年轻成人更可能从第三剂麻腮风疫苗中获益。

研究设计与样本

  • 研究为年轻成人接种第三剂麻腮风疫苗的免疫原性评估,纳入679名18-31岁、有记录已接种两剂麻腮风疫苗者。
  • 接种时间为2009年7月至2010年10月,在接种前、接种后1个月和1年评估风疹中和抗体滴度。

主要发现

  • 接种前(距第二剂约15年)1.8%的参与者风疹抗体滴度低于10 U/ml。
  • 接种后1个月平均滴度升高4.5倍,超过50%的参与者获4倍提升。
  • 接种前滴度低于10 U/ml者应答最高,几何平均滴度比为18.8,92%血清阳转;应答随接种前滴度升高而降低。
  • 接种后1年平均滴度下降但仍显著高于接种前水平。
  • 低水平阳性抗体比例从接种后1个月的3%升至接种后1年的24%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Third doses of measles-mumps-rubella (MMR) vaccine have been administered during mumps outbreaks and in various non-outbreak settings. The immunogenicity of the rubella component has not been evaluated following receipt of a third dose of MMR vaccine. METHODS: Young adults aged 18-31 years with documented two doses of MMR vaccine received a third dose of MMR vaccine between July 2009 and October 2010. Rubella neutralizing antibody titers were assessed before, 1 month, and 1 year after receipt of a third dose of MMR vaccine. RESULTS: Among 679 participants, 1.8% had rubella antibody titers less than 10 U/ml, immediately before vaccination, approximately 15 years after receipt of a second dose of MMR vaccine. One month after receipt of a third dose of MMR vaccine, average titers were 4.5 times higher and >50% of participants had a 4-fold boost. Response was highest among those with titers less than 10 U/ml prior to vaccination (geometric mean titer ratio = 18.8; 92% seroconversion) and decreased with increasing pre-vaccination titers. Average titers declined 1 year postvaccination but remained significantly higher than pre-vaccination levels. The proportion classified as low-positive antibody levels increased from 3% 1 month postvaccination to 24% 1 year postvaccination. CONCLUSIONS: Vaccination with a third dose of MMR vaccine resulted in a robust boosting of rubella neutralizing antibody response that remained elevated 1 year later. Young adults with low rubella titers are more likely to benefit from a third dose of MMR vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. McLean HQ, Fiebelkorn AP, Ogee-Nwankwo A, et al. Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults. Vaccine. 2018. PMID: 30107992. doi:10.1016/j.vaccine.2018.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。